Eton Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that identifies, develops, and commercializes prescription medicines for rare and hard-to-treat diseases. The company's commercial portfolio includes products such as Alkindi Sprinkle for adrenal insufficiency, Increlex for severe primary IGF-1 deficiency, and PKU Golike for phenylketonuria. Geographically, Eton focuses its commercialization efforts within the United States, distributing its branded medicines through specialty pharmacies, hospitals, and healthcare providers. Rather than engaging in early-stage drug discovery, the company leverages the 505(b)(2) regulatory pathway and strategic acquisitions to build its pipeline efficiently. This approach allows Eton to address niche markets with limited competition while providing patient support programs to improve access to its therapies.
